drug_type
RELEVANT_DRUG
intervention_type
Radiopharmaceutical (radioimmunotherapy; radiolabeled monoclonal antibody)
drug_description
Murine IgG1 anti-CD66 (CEACAM) monoclonal antibody conjugated with the beta-emitting radionuclide Yttrium-90 to deliver targeted radiation to CD66+ myeloid/granulocytic cells in bone marrow and spleen for marrow-directed myeloablation.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Yttrium Radioisotopes
drug_category
RADIOIMMUNOCONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Murine IgG1 anti-CD66 (CEACAM) monoclonal antibody conjugated to the beta-emitting radionuclide Yttrium-90; upon binding CD66+ myeloid/granulocytic cells in bone marrow and spleen, it delivers localized radiation that induces DNA damage and cell death, effecting marrow-directed myeloablation and reducing leukemic burden with limited exposure to other tissues.
drug_name
Yttrium-90–labeled anti-CD66 monoclonal antibody (BW250/183)
nct_id_drug_ref
NCT04856215